Publisher
Springer International Publishing
Reference18 articles.
1. American Cancer Society. (2016). Cancer facts & figures 2016. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016/index . Accessed 13 Dec 2016.
2. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016. https://doi.org/10.1056/NEJMoa1606774 .
3. ClinicalTrials.gov Identifier: NCT02477826. www.clinicaltrials.gov . https://clinicaltrials.gov/ct2/show/NCT02477826 .
4. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371–6. https://doi.org/10.1093/annonc/mdt205 .
5. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1–21. https://doi.org/10.1093/annonc/mdx222 .